PAREMYD
LOE Approachinghydroxyamphetamine hydrobromide; tropicamide
NDAOPHTHALMICSOLUTION/DROPS
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAREMYD is a fixed-combination ophthalmic solution containing hydroxyamphetamine hydrobromide and tropicamide, used for mydriasis (pupil dilation) during diagnostic eye examinations. The formulation combines a sympathomimetic agent with an anticholinergic to achieve rapid and sustained mydriasis. It is indicated for dilating the pupil to facilitate comprehensive eye exams and posterior segment evaluation.
LOE Approaching
LOE-stage product with moderate competitive pressure (30%) suggests smaller, defensive brand teams focused on retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PAREMYD offers limited career upside due to its LOE-approaching lifecycle stage and minimal linked job activity. Working on this product is best suited for professionals seeking stable, operationally-focused roles in legacy brand stewardship rather than high-growth commercial or clinical opportunities.
Product ManagerRegulatory Affairs Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.